In particular, survivorship analysis of early LUAD tumor regression candidates at the stage 1–2 interface (e.g., DAPK2 and PLAC9) revealed these genes to serve as positive LUAD prognosis markers (Figure 5A,D). This evidence concerns the gene PLAC9 and neoplasm.